We provide you with 20 years of free, institutional-grade data for CMPI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CMPI. Explore the full financial landscape of CMPI stock.
| Reported Date | CIK | Ticker | Type |
|---|
Checkmate Pharmaceuticals, Inc(NASDAQ:CMPI) 
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanom...
Website: http://www.checkmatepharma.com
Founded: 2015
Full Time Employees: 25 (May 2021)
CEO: Barry A. Labinger
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about CMPI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.